The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Fibroblast activation protein activated antifibrotic peptide delivery attenuates fibrosis in mouse models of liver fibrosis
Open accessAbstract
In liver fibrosis, activated hepatic stellate cells are known to overexpress fibroblast activation protein. Here we report a targeted antifibrotic peptide-delivery system in which fibroblast activation protein, which is overexpressed in fibrotic regions of the liver, liberates the antifibrotic peptide melittin by cleaving a fibroblast activation protein-specific site in the peptide. The promelittin peptide is linked to pegylated and maleimide-functionalized liposomes, resulting in promelittin-modified liposomes. The promelittin-modified liposomes were effective in reducing the viability of activated hepatic stellate cells but not that of control cells. In three types of liver fibrosis mouse models, intravenously administered promelittin-modified liposomes significantly reduces fibrotic regions. In addition, in the bile duct ligation mouse model promelittin-modified liposome-treatment increases overall survival. Although this peptide-delivery concept was tested for liver fibrosis, it can potentially be adapted to other fibrotic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Proposed working mechanism of PRL against liver fibrosis. a Schematic illustration of various liposome formulations. FAP-responsive PRL were synthesized by linking cys-promelittin onto the surface of ML. b In a fibrotic microenvironment, the promelittin moiety on PRL is cleaved by FAP on aHSC. FAP-mediated cleavage of promelittin on PRL releases melittin, which diffuses to nearby aHSC, creating pores in their cell membranes. The resulting reduction in the number of aHSC in fibrotic tissues leads to decreased production of collagens and regression of fibrosis. PL plain PEGylated liposomes; ML maleimide-activated PEGylated liposomes; SCL scrambled cys-promelittin peptide-tagged liposomes; FQL promelittin-mimicking fluorescence-quenched peptide-tagged liposomes; PRL promelittin-modified liposomes; FAP fibroblast activation protein; EDANS, 5-[(2-aminoethyl) amino]naphthalene-1-sulfonic acid; HSC hepatic stellate cell.](https://figures.cochat.ai/paper-figures/9a943498926145f2abcbe578beeba23e/fibroblast-activation-protein-activated-antifibrotic-peptide-delivery-attenuates-figure-1.jpg)






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Because FAP is also implicated in hepatic fibrosis (313, 314), this approach merits further evaluation in MASH.”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [313]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Turning foes to friends: targeting cancer-associated fibroblasts
Chen, X., & Song, E. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0004-1 · Cited by 1,879
Hepatic stellate cells as key target in liver fibrosis
Higashi, T., Friedman, S. L., & Hoshida, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.007 · Cited by 1,485
Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets
Zhang, C.-Y., Yuan, W.-G., He, P., Lei, J.-H., & Wang, C.-X. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i48.10512 · Cited by 594
Elimination Pathways of Nanoparticles
Poon, W., Zhang, Y.-N., Ouyang, B., Kingston, B. R., Wu, J. L. Y., Wilhelm, S., & Chan, W. C. W. (2019) · ACS Nano · doi:10.1021/acsnano.9b01383 · Cited by 575
Roles of dietary glycine, proline, and hydroxyproline in collagen synthesis and animal growth
Li, P., & Wu, G. (2018) · Amino Acids · doi:10.1007/s00726-017-2490-6 · Cited by 550
High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers
Mederacke, I., Dapito, D. H., Affò, S., Uchinami, H., & Schwabe, R. F. (2015) · Nature Protocols · doi:10.1038/nprot.2015.017 · Cited by 549
An improved mouse model that rapidly develops fibrosis in non‐alcoholic steatohepatitis
Matsumoto, M., Hada, N., Sakamaki, Y., Uno, A., Shiga, T., Tanaka, C., Ito, T., Katsume, A., & Sudoh, M. (2013) · International Journal of Experimental Pathology · doi:10.1111/iep.12008 · Cited by 523
Hamson, E. J., Keane, F. M., Tholen, S., Schilling, O., & Gorrell, M. D. (2014) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201300095 · Cited by 496
Liver fibrosis: Direct antifibrotic agents and targeted therapies
Schuppan, D., Ashfaq-Khan, M., Yang, A. T., & Kim, Y. O. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.04.006 · Cited by 435
Cited by
Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)
Wang, S., & Friedman, S. L. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adi0759 · Cited by 158
“Because FAP is also implicated in hepatic fibrosis ( 304 , 305 ), this approach merits further evaluation in MASH.”
ResultFriend or foe? The elusive role of hepatic stellate cells in liver cancer
Cogliati, B., Yashaswini, C. N., Wang, S., Sia, D., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00821-z · Cited by 174
Fabrication of active targeting lipid nanoparticles: Challenges and perspectives
Menon, I., Zaroudi, M., Zhang, Y., Aisenbrey, E. A., & Hui, L. (2022) · Materials Today Advances · doi:10.1016/j.mtadv.2022.100299 · Cited by 144
Liver fibrosis resolution: from molecular mechanisms to therapeutic opportunities
Pei, Q., Yi, Q., & Tang, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119671 · Cited by 121
Liu, J., Liu, J., Mu, W., Ma, Q., Zhai, X., Jin, B., Liu, Y., & Zhang, N. (2024) · ACS Nano · doi:10.1021/acsnano.4c02380 · Cited by 74
Metadata
- Authors
- Lee, J., Byun, J., Shim, G., & Oh, Y.-K.
- Affiliations
- Seoul National University (KR)
- Soongsil University (KR)
- Corresponding author
- Oh, Yu-Kyoung
- Venue
- Nature Communications
- Published
- 2022-03-21
- Volume
- 13
- Issue
- 1
- Pages
- 1516-1516
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC8938482
- OpenAlex
- W4220755333
- Cited by
- 79
- References
- 42
- Citations by year
- 2026: 14 · 2025: 21 · 2024: 18 · 2023: 20 · 2022: 4
- FWCI
- 9.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- liver fibrosis, fibroblast activation protein, melittin, hepatic stellate cells, PEGylated liposomes, bile duct ligation, targeted drug delivery, fibrotic diseases
- MeSH terms
- Animals, Disease Models, Animal, Fibroblasts, Liposomes, Liver, Liver Cirrhosis, Peptides, Mice, Hepatic Stellate Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fibroblast activation protein activated antifibrotic peptide delivery attenuates fibrosis in mouse models of liver fibrosis. https://app.cochat.ai/papers/10.1038/s41467-022-29186-8
- The paper
- Lee, J., Byun, J., Shim, G., & Oh, Y.-K. (2022). Fibroblast activation protein activated antifibrotic peptide delivery attenuates fibrosis in mouse models of liver fibrosis. Nature Communications. https://doi.org/10.1038/s41467-022-29186-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.